| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,313.0 | 1,016.0 |
| Profit before tax | 171.0 | -187.0 |
| Net income | 162.0 | -200.0 |
| EPS (diluted, $ a share) | $0.38 | $-0.51 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +29.2% |
|---|---|
| Operating margin | 9.9% |
10-Q filed with the SEC, NASDAQ: MRNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Moderna, Inc.: key numbers
- Share price
- $215.27Close, Nov 16
- Market cap
- $87.1B
- Shares outstanding
- 404.62MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Moderna, Inc.
All →Moderna $900M Debt Financing with Ares Capital Corporation
Moderna entered into an amendment to its existing Credit and Guaranty Agreement with Ares Capital Corporation, reducing interest rate margins by 0.75 percentage points and extending the maturity date to November 24, 2031. The amendment also extends the availability period for $900 million in delayed draw term loan commitments through November 2029.
- Value
- $900M
- Counterparty
- Ares Capital Corporation
- Term
- through Nov 2031
Moderna Leadership Change
Moderna's Chief Legal Officer, Shannon Thyme Klinger, will retire from the company effective March 31, 2027. Under a transitional services agreement, she will receive $1.63 million in severance plus potential performance bonuses of up to $8 million tied to the outcomes of ongoing litigation with Arbutus, Genevant, Pfizer, and BioNTech.
Moderna Financial Results
Moderna reported Q3 2026 revenue of $1.3 billion, a 29% increase year-over-year, and achieved GAAP net income of $162 million. The company raised its full-year 2026 revenue growth guidance to 15%–25% and highlighted the U.S. FDA approval of mFLUSIVA, its fifth approved product globally.
- Term
- Q3 2026
“We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.”
Stéphane Bancel, Chief Executive Officer of Moderna
“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet. Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company.”
Stéphane Bancel, Chief Executive Officer of Moderna
Moderna President Stephen Hoge Sells $17M of Stock
Stephen Hoge, President, sold 78,369 shares of Moderna, Inc. at $213.47 to $220.72 a share (average $217.10) in 3 transactions, worth $17M in total between Oct 14, 2026 and Oct 15, 2026. Shares held after the trade: 1,636,565 (-2.3%).
- Value
- $17M
- Shares
- 78,369
- Average price
- $217.10
- Role
- President
- Holding change
- -2.3%
- Trade date
- Oct 14, 2026 to Oct 15, 2026
Moderna Executive Compensation
Moderna appointed Juan Andres as its new Chief Operating Officer, effective October 5, 2026, while announcing the retirement of Jerh Collins, Ph.D. Mr. Andres will receive an annual base salary of $800,000, a target bonus of 90%, and a new hire equity award valued at $5 million. The leadership change comes as the company expands its oncology portfolio and scales its global manufacturing network.
- Counterparty
- Juan Andres
Moderna President Stephen Hoge Sells $11.7M of Stock
Stephen Hoge, President, sold 80,575 shares of Moderna, Inc. at $144.13 to $146.07 a share (average $145.10) in 2 transactions, worth $11.7M in total between Sep 14, 2026 and Sep 15, 2026. Shares held after the trade: 1,562,029 (-2.5%).
- Value
- $11.7M
- Shares
- 80,575
- Average price
- $145.10
- Role
- President
- Holding change
- -2.5%
- Trade date
- Sep 14, 2026 to Sep 15, 2026